LifeScan Announces Appointment of Jonathan Salkin as Chief Executive Officer

Succeeds Co-Interim CEOs Michael Hooks, who will remain Chairman of the Board, and James Rushing, who will remain Chief Financial Officer and Executive Vice President

MALVERN, Pa.–(BUSINESS WIRE)–LifeScan (the “Company”), a world leader in blood glucose monitoring, today announced the appointment of Jonathan Salkin as Chief Executive Officer, effective immediately. Salkin will succeed Michael Hooks and James Rushing who have been serving as Co-Interim CEOs since January 2026. Hooks will continue to serve as Chairman of the Board and Rushing will continue in his roles as Executive Vice President and Chief Financial Officer.

Salkin joins LifeScan with more than two decades of experience leading global healthcare, life sciences, and medical technology companies through periods of growth, transformation, and value creation. Most recently, he served as Chief Executive Officer of Antylia Scientific where he led the company through multiple years of strong growth and profitability, spearheading its successful repositioning from a legacy catalog-based laboratory distribution business into a global life sciences and bioprocessing platform. Earlier in his career, Salkin held senior leadership roles at Devicor Medical Products and Cardinal Health.

“I am thrilled to welcome Jon to LifeScan to lead the Company’s next phase of growth,” said Michael Hooks, Chairman of the Board. “Following an extensive and thorough search, Jonathan emerged as the clear choice. His combination of strategic acumen, leadership skills, and a proven track record clearly establishes him as the ideal person to lead LifeScan into a new era of providing diabetes monitoring & management solutions. I look forward to partnering closely with him and the leadership team to collaborate on the opportunities ahead.”

“I’m proud to join LifeScan, a company that has earned the confidence of the diabetes community for more than 40 years,” said Jonathan Salkin, Chief Executive Officer, LifeScan. “LifeScan’s OneTouch® brand is one of the most recognized in glucose monitoring, and more than 20 million people around the world rely on it every day to manage their diabetes. That level of trust carries a meaningful responsibility to continue delivering reliable, innovative solutions that improve outcomes for patients and caregivers. I’m here to build, and I’m glad to be doing it with this team.”

About LifeScan

LifeScan is a global leader in blood glucose monitoring and digital health technology and has a vision to create a world without limits for people with diabetes. More than 20 million people and their caregivers around the world count on LifeScan’s OneTouch® brand products to manage their diabetes. Together, LifeScan and OneTouch® improve the quality of life for people with diabetes with products and digital platforms defined by simplicity, accuracy, and trust. For more information, please visit LifeScan.com.

Contacts

Media Contact 
C Street Advisory Group
lifescan@thecstreet.com